WO2011114338A1 - A process for the preparation of highly pure ambrisentan - Google Patents

A process for the preparation of highly pure ambrisentan Download PDF

Info

Publication number
WO2011114338A1
WO2011114338A1 PCT/IN2010/000153 IN2010000153W WO2011114338A1 WO 2011114338 A1 WO2011114338 A1 WO 2011114338A1 IN 2010000153 W IN2010000153 W IN 2010000153W WO 2011114338 A1 WO2011114338 A1 WO 2011114338A1
Authority
WO
WIPO (PCT)
Prior art keywords
ambrisentan
reaction mass
solution
preparation
ethyl acetate
Prior art date
Application number
PCT/IN2010/000153
Other languages
French (fr)
Inventor
Amala Kompella
Kali Satya Bhujanga Rao Adibhatla
Veera Swamy Balina
Srinivasu Kasa
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Priority to KR1020127026731A priority Critical patent/KR20130054250A/en
Priority to US13/635,299 priority patent/US20130060031A1/en
Priority to PCT/IN2010/000153 priority patent/WO2011114338A1/en
Priority to EP10725507A priority patent/EP2547663A1/en
Priority to CA2792473A priority patent/CA2792473A1/en
Publication of WO2011114338A1 publication Critical patent/WO2011114338A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Definitions

  • the present invention relates to an improved and novel process for the preparation of highly pure (>99.8%) (+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3- diphenylpropionic acid (Ambrisentan) of formula-I
  • Ambrisentan which is (+)-2(S)-(4,6-Dimemylpyrimidin-2-yloxy)-3-methoxy-3,3- diphenylprOpionic acid having the formula - 1 is approved under the trademark "Letairis” by the US Food and Drug Administration for the treatment of Pulmonary artery hypertension(P AH) .
  • methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate (II) is dissolved in DMF and sodium hydride is added. The mixture is stirred for a hour and then 4,6- dimethyl-2-(methylsulfonyl)pyrimidine is added. After stirring at room temperature for 24hours cautious hydrolysis is carried out with water , the pH is adjusted to 5 with acetic acid. , and the solvent is removed under high vacuum. The residue is taken up in ethyl acetate, washed with water and the solvent is distilled out. The residue is mixed with ether and the resulting precipitate is filtered off.
  • step-2 the step-1 product is hydrolyzed in IN KOH solution in dioxane medium at reflux temperature. After reaction completion the reaction mass is washed with ethyl acetate to remove unreacted ester. The pH of the aqueous layer is adjusted with coned. HCl pH 1-2 and extracted with ethyl acetate. After water washing, ethyl acetate is distilled off and the product was liberated by the addition of ether/hexane mixture.
  • the above process adds two more steps to the Route of synthesis viz., esterification and hydrolysis
  • DMF is added dropwise to a suspension of sodium hydride in DMF. The mixture is stirred for an hour and then 4,6-dimemyl-2-memylsulfonylpyrirnidine in DMF is added.
  • mole ratio of S- 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid , 4,6- dime&yl-2-memylsulfonylpyrimidine and sodium hydride is 1:1.3:3.0 .
  • the objective of this invention is to prepare highly pure Ambrisentan through acid addition salts (l:l)of Ambrisentan.
  • Ambrisentan of higher purity results.
  • the main object of the present invention is to provide an improved process for the preparation of highly pure (>99.8%) Ambrisentan
  • Another object of the invention is to provide a process for preparation of salts of Ambrisentan with S(-)4-nitro phenyl ethyl amine or S(-)-phenyl ethyl amine in high purity(>99.8%).
  • Ambrisentan is prepared by .
  • Treating Ambrisentan with S(-)4-nitro phenyl ethylamine or S(-)-phenyl ethyl amine yielding the corresponding addition salt of Ambrisentan iii.
  • the present invention provides the following process for the ⁇ preparation of Ambrisentan
  • the reaction mass is maintained at 25-30°C for 16-17hours
  • aqueous layer pH is adjusted with IN hydrochloride solution to 2-3 during 30-45 minutes
  • reaction mass is maintained under stirring for 2hours at RT
  • reaction mass temperature is raised to reflux
  • reaction mass is maintained at reflux temperature for 1 hours
  • reaction mass is brought to room temperature and maintained at the same
  • Ambrisentan S-(-)4-nitro phenyl ethyl amine /S(-)-phenyl ethyl amine acid addition salts(l .l) are novel and are identified and characterized by chemical analysis, IR, NMR & Mass spectral. Ambrisentan acid addition salts are further converted to Ambrisentan as follows : i. Ambrisentan S-(-)4-nitro phenyl ethyl amine or S(-)-phenyl ethyl amine addition salt is acidified with diluted hydrochloric acid
  • reaction mass is maintained at room temperature for 2-3hours
  • Example- 1 Process for the preparation highly pure Ambrisentan of the formula -I
  • Step-1 Condensation of S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid 4,6-dimethyl-2-(-(methylsulfonyl)pyrimidine in DMF medium
  • DMF(400ml) and S-2-Hydroxy-3-mehoxy- 3,3-diphenyl propionic acid(50g) were, charged and stirred for 30 minutes.
  • sodium hydride(18.9g) was added slowly for lhour and reaction mass was maintained at room temperature for one hours.
  • Step - II Preparation of Ambrisentan S(-)4-nitro phenyl ethylamine addition salt(l:l) : Ambrisentan (60g, purity 99.5%) was dissolved in acetone (900ml) and S-(-)4-nitro phenyl ethyl amine(26.2g) was added to the solution over 30 min . Reaction mass ' ⁇ temperature was raised to reflux and maintained for about l-2hrs. Reaction mass was slowly cooled to room temperature and maintained for about 16-18 hr at the same temperature. The precipitated material was filtered and washed with 200mlof acetone.
  • the product was dried at 60-70°C under vacuum till constant weight.
  • Step - III Preparation of highly pure Ambrisentan from Ambrisentan S(-)P-nitro phenyl ethylamine addition salt (1:1):
  • Ambrisentan .S(-)4-nitro phenyl ethyl amine addition salt(60g) was suspended in DM W water(3L)and stirred for 15minutes.
  • Aqueous IN hydrochloric acid solution(500) was added over a period of 30 min to a pH of 1-2 and maintained at the same temperature for 2-3hours.
  • the precipitated product was filtered and washed with purified water. The product was dried at temperature of 60-70°C till constant weight.
  • Example-2 Process for the preparation highly pure Ambrisentan of the formula -I
  • Step-1 Condensation of S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid and 4,6-dimethyl-2-(-(methylsulfonyl)pyrimidine in THF medium
  • Reaction mass was quenched into DM water (15L) and acidified with diluted hydrochloric acid(600ml). Reaction mass was maintained under stirring for 3hours at room temperature. Filtered compound was dissolved in Ethyl acetate and ethyl acetate layer was extracted with IN sodium hydroxide solution(2L) Sodium hydroxide layer was separated and acidified with IN hydrochloride solution(l .25L) . Reaction mass was maintained under stirring for 2hours . The product of the formula-I was filtered and washed with purified water. It was dried in oven at 60-65 °C
  • Step - II Preparation of Ambrisentan S(-) phenyl ethylamine addition salt(l:l) : Ambrisentan (50g, purity 99.5%) was dissolved in acetone (500ml) and S-(-) phenyl ethyl amine(16.0g) was dissolved in acetone(32ml)added to the solution over 30 min . Reaction mass temperature was raised to reflux and maintained for about l-2hrs. Reaction mass was slowly cooled to room temperature and maintained for about 16-18 hr at the same temperature. The precipitated material was filtered and washed with 200mlof acetone. The product was dried at 60-70°C under vacuum till constant weight. Dry weight : 40g
  • Step - III Preparation of highly pure Ambrisentan from Ambrisentan S(-) phenyl ethylamine addition salt(l :l) :
  • Ambrisentan .S(-) phenyl ethyl amine addition salt(40g) was suspended in DM water(2L)and stirred for 15minutes.
  • Aqueous IN hydrochloric acid solution(330ml) was added over a period of 30 min to a pH of 1-2 and maintained at the same temperature for 2-3hours.
  • the precipitated product was filtered and washed with purified water. The product was dried at temperature of

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an improved and novel process for the preparation of highly pure (>99.8 %) (+)-2(S)-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid (Ambrisentan) of formula (I).

Description

A PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN Field of the invention:
The present invention relates to an improved and novel process for the preparation of highly pure (>99.8%) (+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3- diphenylpropionic acid (Ambrisentan) of formula-I
Figure imgf000002_0001
Formula-I
Back ground of the invention
Ambrisentan which is (+)-2(S)-(4,6-Dimemylpyrimidin-2-yloxy)-3-methoxy-3,3- diphenylprOpionic acid having the formula - 1 is approved under the trademark "Letairis" by the US Food and Drug Administration for the treatment of Pulmonary artery hypertension(P AH) .
Figure imgf000002_0002
Formula-I The preparation of (+)-2(S)-(4,6-Dimethylpyrirnidin-2-yloxy)-3-methoxy-3,3- diphenylpropionic acid(Ambrisentan) having the formula - I is described in WO 9611914; US 5932730(1996, 1998 both to BASF) and J. Med. Chem., 1996, vol.39, No.l l, p.no. 2123-2128
In WO 9611914 and in its equivalent US 5932730 the following route is described (Scheme- 1) for related molecules. The route shown below is adapted for ambrisentan for our study.
Step-I
Figure imgf000003_0001
In this process methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate (II) is dissolved in DMF and sodium hydride is added. The mixture is stirred for a hour and then 4,6- dimethyl-2-(methylsulfonyl)pyrimidine is added. After stirring at room temperature for 24hours cautious hydrolysis is carried out with water , the pH is adjusted to 5 with acetic acid. , and the solvent is removed under high vacuum. The residue is taken up in ethyl acetate, washed with water and the solvent is distilled out. The residue is mixed with ether and the resulting precipitate is filtered off.
In step-2 the step-1 product is hydrolyzed in IN KOH solution in dioxane medium at reflux temperature. After reaction completion the reaction mass is washed with ethyl acetate to remove unreacted ester. The pH of the aqueous layer is adjusted with coned. HCl pH 1-2 and extracted with ethyl acetate. After water washing, ethyl acetate is distilled off and the product was liberated by the addition of ether/hexane mixture. The above process adds two more steps to the Route of synthesis viz., esterification and hydrolysis
1. racemic 2-hydroxy-3-methoxy-3, 3 -diphenylpropionic acid resolution followed by esterification
2. Condensation of the ester with 4,6- dimethyl-2-(methylsulfonyl)pyrimidine to yield Ambrisentan ester followed by hydrolysis to give Ambrisentan
3. When this process is repeated in our laboratory the overall realized yield of final product is less than 15%
4. The purity of the final product obtained is only 95%
In J. Med. Chem., 1996, vol.39, No.l l, p.no. 2123-2128 same chemical route is described using potassium carbonate base in place of sodium hydride at 90°C for step-1. The overall realized yield of final product is less than 10% with a purity of about 92%
Further the preparation of (+)-2(S)-(4,6-Dimemylpyrimidin-2-yloxy)-3 -methoxy-3,3- diphenylpropionic acid(Ambrisentan) having the formula - 1 is described in WO
01/05771(2001 to BASF) In WO 9611914 the following route is described (Scheme-2) for molecules structurally related to ambrisentan .
Scheme -2 :
Figure imgf000005_0001
S-2-hydroxy-3-methoxy 4,6:dimethyl-2-(methylsulfonyl) (+)2(S)-(4,6KJimethylpyrimidin-2- 3,3-diphenyl propionic acid ynm,dine yloxy)-3-methoxy-3, <liphenyl propionic (V) (III) acid (I)
In this process S- 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid(V) is dissolved in
DMF is added dropwise to a suspension of sodium hydride in DMF. The mixture is stirred for an hour and then 4,6-dimemyl-2-memylsulfonylpyrirnidine in DMF is added.
After stirring at room temperature for 24hours it is poured into ice-water , the pH was adjusted to 1 with 2N HC1 , and extracted with diethyl ether. The ether phase is extracted with IN KOH, and the alkaline aqueous phase is readjusted to pH 1 with 2N HC1 and extracted with ether. The solvent is stripped off in vacuum. The residue is stirred in diethyl ether overnight, filtered and dried. The solid obtained in this way is chromatographed on silica gel , allowing isolation of the desired product.
In this process mole ratio of S- 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid , 4,6- dime&yl-2-memylsulfonylpyrimidine and sodium hydride is 1:1.3:3.0 .
By following this method in our laboratory, our observations are :
• the reaction is not going to completion.
· Chemical purity of only 95% is realized
• chiral purity of the product is less than 95%
• column chromatography is necessary to isolate the pure product
There is therefore an unfulfilled need to provide an industrially feasible process for the preparation Ambrisentan devoid of above shortcomings. W
The objective of this invention is to prepare highly pure Ambrisentan through acid addition salts (l:l)of Ambrisentan. When the base is liberated from the acid addition salts, Ambrisentan of higher purity results.
It is surprisingly found by the inventors that when the less pure Ambrisentan is reacted with
S(-)4-nitro phenyl ethylamine or S(-)-phenyl ethyl amine it selectively forms the corresponding acid addition salt, leaving behind the other related substances and impurities which are otherwise difficult to remove by the conventional methods. The S(- )4-nitrophenyl ethyl amine or S(-)-phenyl ethyl amine salt of Ambrisentan is further converted to highly pure Ambrisentan which in turn is converted into other pharmaceutically acceptable salts with higher purity. Summary of the invention
The main object of the present invention is to provide an improved process for the preparation of highly pure (>99.8%) Ambrisentan Another object of the invention is to provide a process for preparation of salts of Ambrisentan with S(-)4-nitro phenyl ethyl amine or S(-)-phenyl ethyl amine in high purity(>99.8%).
Accordingly in the present invention highly pure Ambrisentan is prepared by . Preparing Ambrisentan by the condensation of S(+)2-Hydroxy-3-methoxy-3,3- diphenylpropionic acid with 2-(methylsulfonyl)-4,6-dimethylpyrimidine in presence of sodium hydride base in polar aprotic solvents like DMF or THF ii. Treating Ambrisentan with S(-)4-nitro phenyl ethylamine or S(-)-phenyl ethyl amine yielding the corresponding addition salt of Ambrisentan iii. Acidifying Ambrisentan S(-)4-nitro phenyl ethylamine or S(-)-phenyl ethyl amine salt and isolating Ambrisentan of purity 99.9%
Detailed description of the invention : Thus in accordance with the present invention preparation of Ambrisentan comprises of the following steps
i. preparing Ambrisentan by the condensation of S(+)2-Hydroxy-3-methoxy-3,3- diphenylpropionic acid with 2-(methylsulfonyl)-4,6-dimethylpyrimidine in presence of sodium hydride base in DMF/THF medium in 1 : 1.4:4.3 mole ratio
ii. Treating Ambrisentan with S(-)4-nitro phenyl ethylamine or S(-)-phenyl ethyl amine yielding corresponding addition salts of Ambrisentan iii. Acidifying Ambrisentan S(-)4-nitrophenylethylamine or S(-)-phenyl ethyl amine salt and isolating Ambrisentan of purity 99.85%
In a typical embodiment, the present invention provides the following process for the · preparation of Ambrisentan
S(+) 2-hydroxy-3-methoxy-3, 3 -diphenylpropionic acid (HIP-III) is dissolved in DMF/THF under nitrogen atmosphere at 20-25°C
Sodium hydride is added slowly to the reaction mass during lhour at 25-30°C The mixture is stirred for a hour and then 4,6-dimemyl-2-(memylsulfonyl)pyrimidine in DMF/THF is added drop wise
The reaction mass is maintained at 25-30°C for 16-17hours
After maintenance it is quenched with methanol and poured into ice- water .
aqueous layer pH is adjusted with IN hydrochloride solution to 2-3 during 30-45 minutes
Reaction mass is extracted with Ethyl acetate 8. Ethyl acetate layer is extracted with diluted sodium hydroxide solution
9. Sodium hydroxide layer is acidified with diluted hydrochloric acid
10. reaction mass is maintained under stirring for 2hours at RT
11. The product is Filtered and dried to yield Ambrisentan
Further reacting the resultant base of Ambrisentan with S-(-)4-nitro phenylethyla ine or S(-)-phenyl ethyl amine as follows : i. Ambrisentan is dissolved in acetone and S-(-)4-nitro phenylethylamine/ S-(-)- phenyl ethyl amine is added directly or as a solution in acetone
ii. reaction mass temperature is raised to reflux
iii. reaction mass is maintained at reflux temperature for 1 hours
iv. reaction mass is brought to room temperature and maintained at the same
temperature for
16 -18 hours
iv. The product after filtration and drying at 60-70 °C afforded pure Ambrisentan as corresponding acid addition salt of S-(-)4-nitro phenyl ethylamine or S(-)- phenyl ethylamine
The prepared Ambrisentan S-(-)4-nitro phenyl ethyl amine /S(-)-phenyl ethyl amine acid addition salts(l .l) are novel and are identified and characterized by chemical analysis, IR, NMR & Mass spectral. Ambrisentan acid addition salts are further converted to Ambrisentan as follows : i. Ambrisentan S-(-)4-nitro phenyl ethyl amine or S(-)-phenyl ethyl amine addition salt is acidified with diluted hydrochloric acid
ii. The reaction mass is maintained at room temperature for 2-3hours
iii. The product is filtered and washed with purified water The solid state properties of Ambrisentan thus prepared are illustrated by the following figures :
Fig- 1 - XRPD spectrum of the Ambrisentan prepared by the method disclosed in example -1
Fig-2 - DSC curve of the Ambrisentan prepared by the method disclosed in example- 1
Fig-3 - IR spectrum of the Ambrisentan prepared by the method disclosed in example- 1 Fig- 4 - XRPD spectrum of the Ambrisentan prepared by the method disclosed in example -2
Fig-5— DSC curve of the Ambrisentan prepared by the method disclosed in example- 2
Fig- 6 - IR spectrum of the Ambrisentan prepared by the method disclosed in example-2
The required S- 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid and 4,6-dimethyl-2- (methylsulfonyl)pyrimidine can be prepared by the prior art processes
The details of the inventions are given in the Examples which are provided for^ illustration only and therefore the Examples should not be construed to limit the scope of the invention.
EXAMPLES
Example- 1 : Process for the preparation highly pure Ambrisentan of the formula -I
Step-1 : Condensation of S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid 4,6-dimethyl-2-(-(methylsulfonyl)pyrimidine in DMF medium Into a 1L round bottomed flask a mixture of DMF(400ml) and S-2-Hydroxy-3-mehoxy- 3,3-diphenyl propionic acid(50g) were, charged and stirred for 30 minutes. sodium hydride(18.9g) was added slowly for lhour and reaction mass was maintained at room temperature for one hours. 2-(methylsulfonyl)-4,6-dimethyl pyrimidine(47.8g) was dissolved in DMF( 100ml) and added to the reaction mass at room temperature during 45-60 minutes and reaction mass was maintained overnight under stirring. After reaction completion methanol(50ml)l was added slowly to the reaction mass during 30 minutes. Reaction mass was quenched into DM water (5L) and acidified with diluted hydrochloric acid(600ml). Aqueous layer was extracted with ethyl acetate(2x500ml) and combined ethyl acetate layer was extracted with IN sodium hydroxide solution. Sodium hydroxide layer was separated and acidified with IN hydrochloride solution . Reaction mass was maintained under stirring for 2hours . The product of the formula-I was filtered and washed with purified water. It was dried in oven at 60-65°C
Dry weight : 60g
Purity by HPLC : related : 99.5%
Chiral : 99.5%
Step - II : Preparation of Ambrisentan S(-)4-nitro phenyl ethylamine addition salt(l:l) : Ambrisentan (60g, purity 99.5%) was dissolved in acetone (900ml) and S-(-)4-nitro phenyl ethyl amine(26.2g) was added to the solution over 30 min . Reaction mass ' temperature was raised to reflux and maintained for about l-2hrs. Reaction mass was slowly cooled to room temperature and maintained for about 16-18 hr at the same temperature. The precipitated material was filtered and washed with 200mlof acetone.
The product was dried at 60-70°C under vacuum till constant weight.
Dry weight : 60g
Melting point : 156-160-deg C
Purity by HPLC : related : 99.95% (Single impurity less than 0.1 %)
Chiral : 99.85% ( single impurity less than 0.1 %)
Step - III : Preparation of highly pure Ambrisentan from Ambrisentan S(-)P-nitro phenyl ethylamine addition salt (1:1):
Ambrisentan .S(-)4-nitro phenyl ethyl amine addition salt(60g) was suspended in DM W water(3L)and stirred for 15minutes. Aqueous IN hydrochloric acid solution(500) was added over a period of 30 min to a pH of 1-2 and maintained at the same temperature for 2-3hours.The precipitated product was filtered and washed with purified water. The product was dried at temperature of 60-70°C till constant weight.
Dry weight of Ambrisentan : 42g
Purity by HPLC : related : 99.95% (Single impurity less than 0.1%)
Chiral purity : 99.85% (Single impurity less than 0.1%)
Example-2 : Process for the preparation highly pure Ambrisentan of the formula -I
.
Step-1 : Condensation of S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid and 4,6-dimethyl-2-(-(methylsulfonyl)pyrimidine in THF medium
Into a 1L round bottomed flask a mixture of THF(IL) and S-2-Hydroxy-3-mehoxy-3,3- diphenyl propionic acid(50g) were charged and stirred for 30 minutes. sodium hydride(18.9g) was added slowly for lhour and reaction mass was maintained at room temperature for one hours. 2-(methylsulfonyl)-4,6-dimethyl pyrimidine(47.8g) was * dissolved in THF(500ml) and added to the reaction mass at room temperature during 45- 60 minutes and reaction mass was maintained overnight under stirring. After reaction Ji completion methanol(50ml) was added slowly to the reaction mass during 30 minutes. Reaction mass was quenched into DM water (15L) and acidified with diluted hydrochloric acid(600ml). Reaction mass was maintained under stirring for 3hours at room temperature. Filtered compound was dissolved in Ethyl acetate and ethyl acetate layer was extracted with IN sodium hydroxide solution(2L) Sodium hydroxide layer was separated and acidified with IN hydrochloride solution(l .25L) . Reaction mass was maintained under stirring for 2hours . The product of the formula-I was filtered and washed with purified water. It was dried in oven at 60-65 °C
Dry weight : 50g
Purity by HPLC : related : 99.4%
Chiral : 99.36% Step - II : Preparation of Ambrisentan S(-) phenyl ethylamine addition salt(l:l) : Ambrisentan (50g, purity 99.5%) was dissolved in acetone (500ml) and S-(-) phenyl ethyl amine(16.0g) was dissolved in acetone(32ml)added to the solution over 30 min . Reaction mass temperature was raised to reflux and maintained for about l-2hrs. Reaction mass was slowly cooled to room temperature and maintained for about 16-18 hr at the same temperature. The precipitated material was filtered and washed with 200mlof acetone. The product was dried at 60-70°C under vacuum till constant weight. Dry weight : 40g
Melting point : 88-90-deg C
Purity by HPLC : related : 99.90%(Single impurity less than 0.1 %)
Chiral : 99.82% (Single impurity less than 0.1%)
Step - III : Preparation of highly pure Ambrisentan from Ambrisentan S(-) phenyl ethylamine addition salt(l :l) :
Ambrisentan .S(-) phenyl ethyl amine addition salt(40g) was suspended in DM water(2L)and stirred for 15minutes. Aqueous IN hydrochloric acid solution(330ml) was added over a period of 30 min to a pH of 1-2 and maintained at the same temperature for 2-3hours.The precipitated product was filtered and washed with purified water. The product was dried at temperature of
60-70°C till constant weight.
Dry weight of Ambrisentan : 30g
Purity by HPLC : related : 99.90% (Single impurity less than 0.1 %)
Chiral purity : 99.80% (Single impurity less than 0.1%)
Advantages of the invention
1) Ambrisentan produced in more than 99.8% chemical purity.
2) The chiral purity of Ambrisentan by the process of the present invention is about 99.8%

Claims

We Claim:
1. Novel process for the preparation of Ambrisentan comprising a) Dissolving S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid in DMF under nitrogen atmosphere at 20-25°C
b) Adding Sodium hydride slowly to the reaction mass during lhour at 25-30°C c) stirring reaction mixture for one hour
d) adding 4,6-dimethyl-2-(methylsulfonyl)pyrimidine solution in DMF drop wise e) Mamtaining reaction mass at 25-30°C for 16-17hours
f) quenching reaction mass with methanol and pouring into ice-water .
g) aqueous layer pH adjustment with IN hydrochloride solution
h) extraction of reaction mass with ethyl acetate
i) extraction of ethyl acetate layer with IN sodium hydroxide solution
j) Acidification of ethyl acetate layer with IN hydrochloric acid slution
k) Maintenance of reaction mass under stirring for 2hours
1) Filtering to yield Ambrisentan .
Novel process for the preparation of highly pure (>99.8%) Ambrisentan comprising the following steps
I. Dissolving Ambrisentan in acetone and addition of S-(-)4-nitro phenyl ethyl amine directly or as a solution in acetone
II. Raising reaction mass temperature to reflux
III. Maintenance of reaction mass at reflux temperature for lhour
IV. Cooling reaction mass to room temperature and maintaining at the same temperature for 16 -18 hours
V. Filtering and to yield pure Ambrisentan as an acid addition salt of S-(-
)4-nitro phenylethylamine
VI. Acidification of Ambrisentan S-(-)4-nitro phenyl ethyl amine with diluted hydrochloric acid
1 VII. Maintenance at room temperature for 2-3hours
VIII. Filtering to yield Ambrisentan of high purity(>99.8%)
3. Novel process for the preparation of Ambrisentan comprising a) Dissolving S(+) 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid in THF under nitrogen atmosphere at 20-25°C
b) Adding Sodium hydride slowly to the reaction mass during lhour at 25-30°C c) stirring reaction mixture for one hour
d) adding 4,6-dimemyl-2-(memylsulfonyl)pyrimidine solution in THF drop wise e) Maintaining reaction mass at 25-30°C for 16-17hours
f) quenching reaction mass with methanol and pouring into ice-water .
g) aqueous layer pH adjustment with IN hydrochloride solution
h) Mamtaining reaction under stirring for 3hours
i) Filtration and dissolution of filtered solid in ethyl acetate
j) extraction of ethyl acetate layer with IN sodium hydroxide solution
k) Acidification of ethyl acetate layer with IN hydrochloric acid solution
1) Maintenance of reaction mass under stirring for 2hours
m) Filtering to yield Ambrisentan
4. Novel process for the preparation of highly pure (>99.8) Ambrisentan comprising the following steps
I. Dissolving Ambrisentan in acetone and addition of S-(-) phenyl ethyl amine directly or as a solution in acetone
II. Raising reaction mass temperature to reflux
III. Maintenance of reaction mass at reflux temperature for lhour
IV. Cooling reaction mass to room temperature and maintaining at the same temperature for 16 - 18 hours
V. Filtering and to yield pure Ambrisentan as an acid addition salt of S-(-) phenyl ethylamine
2 VI. Acidification of Ambrisentan S-(-) phenyl ethyl amine addition salt with diluted hydrochloric acid
VII. Maintenance at room temperature for 2-3hours
VIII. Filtering to yield Ambrisentan of high purity(>99.8%)
5. A (1 : 1) addition salt of ambrisentan and S-(-)4-nitro phenyl ethyl amine as a novel pharmaceutically acceptable salt of Ambrisentan
6. A (1 :1) addition salt of ambrisentan and S-(-) phenyl ethyl amine as a novel pharmaceutically acceptable salt of Ambrisentan
7. A novel method of preparing highly pure (> 99.8%) Ambrisentan essentially as herein described with reference to example- 1 and example-2
PCT/IN2010/000153 2010-03-15 2010-03-15 A process for the preparation of highly pure ambrisentan WO2011114338A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020127026731A KR20130054250A (en) 2010-03-15 2010-03-15 A process for the preparation of highly pure ambrisentan
US13/635,299 US20130060031A1 (en) 2010-03-15 2010-03-15 Process for the preparation of highly pure ambrisentan
PCT/IN2010/000153 WO2011114338A1 (en) 2010-03-15 2010-03-15 A process for the preparation of highly pure ambrisentan
EP10725507A EP2547663A1 (en) 2010-03-15 2010-03-15 A process for the preparation of highly pure ambrisentan
CA2792473A CA2792473A1 (en) 2010-03-15 2010-03-15 A process for the preparation of highly pure ambrisentan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2010/000153 WO2011114338A1 (en) 2010-03-15 2010-03-15 A process for the preparation of highly pure ambrisentan

Publications (1)

Publication Number Publication Date
WO2011114338A1 true WO2011114338A1 (en) 2011-09-22

Family

ID=42813438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000153 WO2011114338A1 (en) 2010-03-15 2010-03-15 A process for the preparation of highly pure ambrisentan

Country Status (5)

Country Link
US (1) US20130060031A1 (en)
EP (1) EP2547663A1 (en)
KR (1) KR20130054250A (en)
CA (1) CA2792473A1 (en)
WO (1) WO2011114338A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524424A (en) * 2012-07-04 2014-01-22 天津药物研究院 Crystal form VI of ambrisentan as well as preparation method and application thereof
CN103524425A (en) * 2012-07-04 2014-01-22 天津药物研究院 Crystal form V of ambrisentan as well as preparation method and application thereof
WO2014139086A1 (en) * 2013-03-12 2014-09-18 江苏康缘药业股份有限公司 Method for preparing ambrisentan

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011914A1 (en) 1994-10-14 1996-04-25 Basf Aktiengesellschaft New carboxylic acid derivatives, their preparation and their use
WO2001005771A1 (en) 1999-07-20 2001-01-25 Basf Aktiengesellschaft Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011914A1 (en) 1994-10-14 1996-04-25 Basf Aktiengesellschaft New carboxylic acid derivatives, their preparation and their use
US5932730A (en) 1994-10-14 1999-08-03 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use
WO2001005771A1 (en) 1999-07-20 2001-01-25 Basf Aktiengesellschaft Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE JOURNAL OF MEDICINAL CHEM [Online] 1 May 1996 (1996-05-01), RIECHERS H ET AL: "DISCOVERY AND OPTIMIZATION OF A NOVEL CLASS OF ORALLY ACTIVE NONPEPTIDIC ENDOTHELIN-A RECEPTOR ANTAGONISTS", XP002023887, retrieved from CHEMICAL PAN - 91407 *
J. MED. CHEM., vol. 39, no. 11, 1996, pages 2123 - 2128
J. MED. CHEM., vol. 39, no. LL, 1996, pages 2123 - 2128

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524424A (en) * 2012-07-04 2014-01-22 天津药物研究院 Crystal form VI of ambrisentan as well as preparation method and application thereof
CN103524425A (en) * 2012-07-04 2014-01-22 天津药物研究院 Crystal form V of ambrisentan as well as preparation method and application thereof
WO2014139086A1 (en) * 2013-03-12 2014-09-18 江苏康缘药业股份有限公司 Method for preparing ambrisentan

Also Published As

Publication number Publication date
KR20130054250A (en) 2013-05-24
CA2792473A1 (en) 2011-09-22
EP2547663A1 (en) 2013-01-23
US20130060031A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
US8962832B2 (en) Process for the preparation of ambrisentan and novel intermediates thereof
WO2013026391A1 (en) Synthesis method of azoxystrobin and exclusive intermediate in the synthesis thereof
EP2602250B1 (en) Method for preparing rosuvastatin calcium intermediate
CA2848631A1 (en) Rilpivirine hydrochloride
KR20170029506A (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
US7227021B2 (en) Process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
US20090099362A1 (en) Process for the preparation of gabapentin hydrochloride
EP2547663A1 (en) A process for the preparation of highly pure ambrisentan
US20130184490A1 (en) Process to prepare s-2-hydroxy-3-methoxy-3,3-diphenyl propionic acid
US6187926B1 (en) Process for producing quinolone derivatives
CN109988070B (en) Intermediate of trans-1-hydroxy-1- (trifluoromethyl) -3-aminocyclobutane hydrochloride, preparation method and application
CA3136883A1 (en) Process for the preparation of fungicidally active strobilurin compounds and intermediates thereof
EP3356372B1 (en) Novel process for preparing thienopyrimidine compound and intermediates used therein
CN114685375A (en) Preparation method of [2- (6-chloropyrimidine-4-oxygen) phenyl ] -3, 3-dimethoxyacrylic acid methyl ester
US9212120B2 (en) Process for preparing spiro[2.5]octane-5,7-dione
US20140275535A1 (en) Acid addition salts of bosentan
CN104447527A (en) Method for preparing pyridine-2,3-dicarboxylic ester compound
US7223882B2 (en) Process for producing triterpene derivative
JP4356111B2 (en) Process for producing N- (2-amino-1,2-dicyanovinyl) formamidine
US20130245259A1 (en) Process for the preparation of bosentan monohydrate
JP2003500333A (en) Method for producing 4-[(2 &#39;, 5&#39;-diamino-6&#39;-halogenpyrimidin-4&#39;-yl) amino] cyclopent-2-enylmethanol
JP2000327629A (en) Phenylacetic acid derivative, benzonitrile derivative and production thereof
WO2023100110A1 (en) Process for preparing brivaracetam
WO2011121598A1 (en) Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof
JP2000327652A (en) Phthalonitrile derivative and its production

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10725507

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2792473

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010725507

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127026731

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13635299

Country of ref document: US